Comparison of intraoperative cortisol levels after preoperative hydrocortisone administration versus placebo in patients without adrenal insufficiency undergoing endoscopic transsphenoidal removal of nonfunctioning pituitary adenomas: a double-blind randomized trial.

OBJECTIVE In this double-blind randomized trial, the necessity of preoperative steroid administration in patients without adrenal insufficiency (AI) undergoing endoscopic transsphenoidal surgery (ETSS) for pituitary adenoma was evaluated. METHODS Forty patients with and without AI, defined as a peak cortisol level > 18 µg/dl on the insulin tolerance test or rapid adrenocorticotropic hormone (ACTH) test, undergoing ETSS for nonfunctioning pituitary adenomas were randomly allocated to treatment with either 100 mg of preoperative hydrocortisone (group HC, n = 20) or normal saline (group C, n = 20). The patients with pituitary apoplexy, the use of a drug within the last 3 months that could affect the hypothalamic-pituitary-adrenal axis, or a previous history of brain or adrenal surgery were excluded. Intraoperative cortisol and ACTH levels were measured after anesthesia induction, dura incision, and tumor removal, and at the end of surgery. Intraoperative hypotension, early postoperative AI, and postoperative 3-month pituitary function were investigated. RESULTS Intraoperative serum cortisol levels were significantly higher in the HC group than in the C group after anesthesia induction (median 69.0 µg/dl [IQR 62.2-89.6 µg/dl] vs 12.7 µg/dl [IQR 8.4-18.2 µg/dl], median difference 57.5 µg/dl [95% CI 33.0-172.9 µg/dl]), after dura incision (median 53.2 µg/dl [IQR 44.9-63.8 µg/dl] vs 6.4 [IQR 4.8-9.2 µg/dl], median difference 46.6 µg/dl [95% CI 13.3-89.2 µg/dl]), after tumor removal (median 49.5 µg/dl [IQR 43.6-62.4 µg/dl] vs 9.2 µg/dl [IQR 5.75-16.7 µg/dl], median difference 39.4 µg/dl [95% CI 0.3-78.1 µg/dl]), and at the end of surgery (median 46.9 µg/dl [IQR 40.1-63.4 µg/dl] vs 16.9 µg/dl [IQR 12.1-23.2 µg/dl], median difference 32.2 µg/dl [95% CI -42.0 to 228.1 µg/dl]). Serum ACTH levels were significantly lower in group HC than in group C after anesthesia induction (median 3.9 pmol/L [IQR 1.7-5.2 pmol/L] vs 6.9 pmol/L [IQR 3.9-11.9 pmol/L], p = 0.007). No patient showed intraoperative hypotension due to AI. Early postoperative AI was observed in 3 and 5 patients in groups HC and C, respectively. The postoperative 3-month pituitary hormone outcomes including ACTH deficiency were not different between groups. CONCLUSIONS Preoperative steroid administration may be unnecessary in patients without AI undergoing ETSS for nonfunctioning pituitary adenomas. However, a further large-scale study is needed to determine whether preoperative steroid administration has a significant impact on clinically meaningful events such as perioperative AI and postoperative 3-month ACTH deficiency in these patients.Korean Clinical Trial Registry no.: KCT0002426 (https://cris.nih.go.kr/cris/).

[1]  B. Martin,et al.  Lower-dose perioperative steroid protocol during endoscopic endonasal pituitary adenoma resection , 2019, Surgical neurology international.

[2]  M. Weiss,et al.  Clinical utility of routine postoperative morning cortisol monitoring in detecting new hypothalamic-pituitary-adrenal axis insufficiency following endoscopic transsphenoidal surgery for sellar lesions. , 2019, Journal of neurosurgery.

[3]  M. Chicoine,et al.  Withholding Perioperative Steroids in Patients Undergoing Transsphenoidal Resection for Pituitary Disease: Randomized Prospective Clinical Trial to Assess Safety. , 2018, Neurosurgery.

[4]  P. Siesjö,et al.  Perioperative serum cortisol levels in ACTH sufficient and ACTH deficient patients during transsphenoidal surgery of pituitary adenoma , 2018, Endocrine.

[5]  A. Hong,et al.  Endoscopic Transsphenoidal Surgery Outcomes in 331 Nonfunctioning Pituitary Adenoma Cases After a Single Surgeon Learning Curve. , 2018, World neurosurgery.

[6]  C. Collard,et al.  Perioperative Steroid Management: Approaches Based on Current Evidence , 2017, Anesthesiology.

[7]  Timothy R. Smith,et al.  Safety of remifentanil in transsphenoidal surgery: A single-center analysis of 540 patients , 2017, Journal of Clinical Neuroscience.

[8]  M. Swaminathan,et al.  Neuroendocrine stress response: implications for cardiac surgery-associated acute kidney injury. , 2017, Romanian journal of anaesthesia and intensive care.

[9]  S. Corsello,et al.  Current best practice in the management of patients after pituitary surgery , 2017, Therapeutic advances in endocrinology and metabolism.

[10]  M. Molitch.  Diagnosis and Treatment of Pituitary Adenomas: A Review , 2017, JAMA.

[11]  Chiyuan Ma,et al.  Is Peri-Operative Steroid Replacement Therapy Necessary for the Pituitary Adenomas Treated with Surgery? A Systematic Review and Meta Analysis , 2015, PloS one.

[12]  M. Friedman.  The human stress response. , 2015 .

[13]  Jacqueline M. Regan,et al.  Selective Use of Peri-Operative Steroids in Pituitary Tumor Surgery: Escape from Dogma , 2013, Front. Endocrinol..

[14]  M. Cusimano,et al.  Transphenoidal surgery without steroid replacement in patients with morning serum cortisol below 9 μg/dl (250 Nmol/l) , 2012, Acta Neurochirurgica.

[15]  M. Zwahlen,et al.  Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. , 2012, The Journal of clinical endocrinology and metabolism.

[16]  A. Pesenti,et al.  A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia during elective craniotomy , 2012, European journal of anaesthesiology.

[17]  David S. Smith,et al.  A Review of Perioperative Glucose Control in the Neurosurgical Population , 2009, Journal of diabetes science and technology.

[18]  G. Neuloh,et al.  Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study. , 2009, Journal of neurosurgery.

[19]  D. D. de Lange,et al.  Perioperative glucocorticosteroid supplementation is not supported by evidence. , 2008, European journal of internal medicine.

[20]  P. Giannoudis,et al.  Surgical stress response. , 2006, Injury.

[21]  W. Vale,et al.  The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress , 2006, Dialogues in clinical neuroscience.

[22]  Berthold Bein,et al.  Neuroendocrine Stress Response and Heart Rate Variability: A Comparison of Total Intravenous Versus Balanced Anesthesia , 2005, Anesthesia and analgesia.

[23]  A. Matsuno,et al.  High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions. , 2005, Endocrine journal.

[24]  W. Inder,et al.  Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  J. O'Callaghan,et al.  Neuroendocrine aspects of the response to stress. , 2002, Metabolism: clinical and experimental.

[26]  R. Eastell,et al.  Glucocorticoid replacement therapy: are patients over treated and does it matter? , 1997, Clinical endocrinology.

[27]  F. Petraglia,et al.  Involvement of μ-opioid receptors in the modulation of pituitary-adrenal axis in normal and stressed rats , 1995, Journal of endocrinological investigation.

[28]  R. Astorga,et al.  Evaluation of the pituitary-adrenal axis before, during and after pituitary adenomectomy. Is perioperative glucocorticoid therapy necessary? , 1990, Acta Endocrinologica.

[29]  W. Selman,et al.  Evaluation of the hypothalamic-pituitary-adrenal axis immediately after pituitary adenomectomy: is perioperative steroid therapy necessary? , 1988, The Journal of clinical endocrinology and metabolism.

[30]  S. Berson,et al.  Radioimmunoassay of ACTH in plasma. , 1968, The Journal of clinical investigation.

[31]  L. Lewis,et al.  Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment. , 1953, Annals of internal medicine.

[32]  C. Fraser,et al.  Adrenal atrophy and irreversible shock associated with cortisone therapy. , 1952, Journal of the American Medical Association.